Difemerine

Summary

Difemerine (CHEMBL3304486) is an approved small molecule (ATC A03AA09); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AA09
• Indications: 1 condition
• Chemistry: 327.4 Da · C20H25NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3304486
Name	Difemerine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	17843092
ATC	A03AA09
Molecular formula	C20H25NO3
Molecular weight	327.4
InChIKey	WJIZVQNUJVMJAZ-UHFFFAOYSA-N

SMILES: CC(C)(CN(C)C)OC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O

IUPAC name: [1-(dimethylamino)-2-methylpropan-2-yl] 2-hydroxy-2,2-diphenylacetate

Also known as: Difemerina, Difemerine, DIFEMERINE

Parent form; salt/anhydrous children: CHEMBL3301670

Patent coverage: 158 distinct patent families (646 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).